Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Deals

Easy-Flow Medical Secures Angel Funding for Peripheral Device Development

Fineline Cube Oct 25, 2022

China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens...

Company Drug

Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer

Fineline Cube Oct 24, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...

Company Deals

Zhejiang Pushkang Biotech Raises RMB 100M in Series C+ Financing

Fineline Cube Oct 24, 2022

China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised...

Company Deals R&D

Sinovac Partners with Colombia University to Boost Vaccine R&D

Fineline Cube Oct 24, 2022

China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...

Company Deals

SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices

Fineline Cube Oct 24, 2022

Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100...

Company Drug

MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8

Fineline Cube Oct 24, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...

Company Drug

Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma

Fineline Cube Oct 24, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...

Company Drug

Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications

Fineline Cube Oct 24, 2022

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...

Company Drug

AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial

Fineline Cube Oct 24, 2022

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...

Company Deals

Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M

Fineline Cube Oct 24, 2022

China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...

Company

Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline

Fineline Cube Oct 24, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...

Company

Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce

Fineline Cube Oct 21, 2022

US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...

Drug R&D

Sinopharm’s Wuhan Institute Isolates Monkeypox Strains, Begins Vaccine Research

Fineline Cube Oct 21, 2022

China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...

Company Deals

CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization

Fineline Cube Oct 21, 2022

China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...

Policy / Regulatory

Fujian Procurement Center Announces VBP for Cardiac and Laparoscopic Medical Consumables

Fineline Cube Oct 21, 2022

The Fujian drug and device joint procurement center has released two separate notifications regarding the...

Policy / Regulatory

NMPA Releases 61st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...

Company Drug

Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA

Fineline Cube Oct 21, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...

Company Drug

Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid

Fineline Cube Oct 21, 2022

Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...

Company Drug

Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China

Fineline Cube Oct 21, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...

Company Drug

China Approves GSK’s Juluca for HIV-1 Infection

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...

Posts pagination

1 … 548 549 550 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.